Palatin Technologies Inc (PTN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Palatin Technologies Inc stock (PTN) is currently trading at $21.00. Palatin Technologies Inc PS ratio (Price-to-Sales) is 4.07. Analyst consensus price target for PTN is $51.50. WallStSmart rates PTN as Sell.
- PTN PE ratio analysis and historical PE chart
- PTN PS ratio (Price-to-Sales) history and trend
- PTN intrinsic value — DCF, Graham Number, EPV models
- PTN stock price prediction 2025 2026 2027 2028 2029 2030
- PTN fair value vs current price
- PTN insider transactions and insider buying
- Is PTN undervalued or overvalued?
- Palatin Technologies Inc financial analysis — revenue, earnings, cash flow
- PTN Piotroski F-Score and Altman Z-Score
- PTN analyst price target and Smart Rating
Palatin Technologies Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Palatin Technologies Inc (PTN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Palatin Technologies Inc (PTN) Key Strengths (1)
Keeps $53 of every $100 in revenue after operating costs
Supporting Valuation Data
Palatin Technologies Inc (PTN) Areas to Watch (8)
Company is destroying shareholder value
Revenue declining -80.10%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 14.27%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.1x annual revenue
Premium pricing at 3.3x book value
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Palatin Technologies Inc (PTN) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin. Profitability is solid with Operating Margin at 52.70%.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Some valuation metrics including PEG Ratio (1.62), Price/Sales (4.07), Price/Book (3.31) suggest expensive pricing. Growth concerns include Revenue Growth at -80.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -623.00%, Profit Margin at -54.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -623.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -80.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PTN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PTN's Price-to-Sales ratio of 4.07x sits near its historical average of 4.27x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 4.74x set in Mar 2026, and 3% above its historical low of 3.97x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Palatin Technologies Inc (PTN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Palatin Technologies Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 9M with 80% decline year-over-year. The company is currently unprofitable, posting a -54.3% profit margin.
Key Findings
Spending 49% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 80% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -54.3% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Palatin Technologies Inc.
Bottom Line
Palatin Technologies Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Palatin Technologies Inc(PTN)
AMEX
HEALTHCARE
BIOTECHNOLOGY
USA
Palatin Technologies, Inc., a specialty biopharmaceutical company, develops targeted receptor-specific therapies for the treatment of various diseases in the United States. The company is headquartered in Cranbury, New Jersey.